Adenoma of large intestine
|
0.030 |
Biomarker
|
disease |
BEFREE |
AURKA gene is associated with progressive colorectal adenomas but is uninvolved in the development of nonprogressive adenomas.
|
25596657 |
2015 |
Adenoma of large intestine
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Chromosome 20q DNA copy number status correlated significantly with TPX2 and AURKA protein levels in a series of colorectal adenomas and carcinomas.
|
22207630 |
2012 |
Adenoma of large intestine
|
0.030 |
Biomarker
|
disease |
BEFREE |
AURKA and DSN1 are thus critical for chromosome 20q amplification-associated malignant transformation in CRA.
|
27329586 |
2016 |
Adult Acute Monoblastic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Segmental amplification of MLL gene associated with high expression of AURKA and AURKB genes in a case of acute monoblastic leukemia with complex karyotype.
|
20303016 |
2010 |
Adult Acute Myeloblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia.
|
29654398 |
2018 |
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Inhibition of AURKA suppressed glioblastoma cell growth.
|
20593995 |
2010 |
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells.
|
31754113 |
2019 |
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results demonstrated that miR-124 inhibited glioblastoma growth and potentiated chemosensitivity by targeting AURKA, which may represent promising targets and rational therapeutic options for glioblastoma.
|
28242198 |
2017 |
Adult Glioblastoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
The AURKA inhibitor alisertib exhibits antiproliferative activity against glioblastoma in vitro and in vivo.
|
29396807 |
2018 |
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
AURKA kinase inhibition could effectively attenuate Wnt signaling, thereby inhibiting the self-renewal and tumorigenicity of GICs, and may be a novel target for glioblastoma treatment strategies.
|
23761169 |
2013 |
Adult Glioblastoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Differential expression of those genes was detected between human normal glial cells and glioblastoma cells by quantitative reverse transcription polymerase chain reaction (P < 0.05), and the survival curve analysis showed that the patients with low expression of gene AURKA, NDC80, KIF4A, and NUSAP1 had a significant favorable prognosis (P < 0.05).
|
28989042 |
2018 |
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
We show that AURKA and KDR genes are hub driver genes in glioblastoma with bioinformatics technology including WGCNA analysis, PPI network, GO, KEGG analysis and GSEA analysis.
|
31706255 |
2019 |
Adult Glioblastoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
We have previously shown that the selective AURKA inhibitor alisertib potently inhibits growth of glioblastoma cells.
|
31011934 |
2019 |
Adult Liposarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Overall, our study showed that selinexor treatment restored tumor suppressive function of IGFBP5 and inhibited aurora kinase A and B in liposarcoma cells supporting the usefulness of selinexor as a potential therapeutic strategy for the treatment of this cancer.
|
27893412 |
2017 |
Adult Liposarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Expression profile‑driven discovery of AURKA as a treatment target for liposarcoma.
|
31485600 |
2019 |
Adult Liver Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
|
27213815 |
2016 |
Adult Liver Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
This HCC marker set contained several cancer-related genes, including serine/threonine kinase 15 (STK15), which has been implicated in chromosome segregation abnormalities but which has not been linked previously with liver cancer.
|
12591738 |
2003 |
Adult Malignant Peripheral Nerve Sheath Tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
|
22811580 |
2012 |
Adult Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival.
|
15126347 |
2004 |
Adult Myelodysplastic Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH.
|
23092930 |
2013 |
Adult Non-Hodgkin Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that Aurora2/BTAK/STK15 is an effective candidate to indicate not only disease activity but also tumorigenesis of non-Hodgkin's lymphoma.
|
12716366 |
2003 |
Adult Non-Hodgkin Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.
|
21879811 |
2012 |
Advanced lung cancer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer.
|
23053267 |
2012 |
Advanced Urothelial Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib.
|
28155045 |
2017 |
Aggressive Adult Non-Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-Hodgkin's lymphoma.
|
12716366 |
2003 |